CU23415B7 - Derivados de 2,6- quinolinilo y 2,6- naftilo, procesos para su preparación y sus usos - Google Patents

Derivados de 2,6- quinolinilo y 2,6- naftilo, procesos para su preparación y sus usos

Info

Publication number
CU23415B7
CU23415B7 CU20040252A CU20040252A CU23415B7 CU 23415 B7 CU23415 B7 CU 23415B7 CU 20040252 A CU20040252 A CU 20040252A CU 20040252 A CU20040252 A CU 20040252A CU 23415 B7 CU23415 B7 CU 23415B7
Authority
CU
Cuba
Prior art keywords
processes
preparation
derivatives
quinolinilo
naftilo
Prior art date
Application number
CU20040252A
Other languages
English (en)
Inventor
Gerald Guillaumet
Sylvain Routier
Thierry Kogej
La Veleye Francoise De
Thierry Demaude
Marie-Agnes Lassoie
Laurent Knerr
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of CU23415B7 publication Critical patent/CU23415B7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invención se refiere a derivados de 2,6-quinolonilo y 2,6-naftilo, procesos para la preparación de los mismos, composiciones farmacéuticas que los contienen y su uso como productos farmacéuticos.
CU20040252A 2002-04-30 2004-11-01 Derivados de 2,6- quinolinilo y 2,6- naftilo, procesos para su preparación y sus usos CU23415B7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02009746 2002-04-30

Publications (1)

Publication Number Publication Date
CU23415B7 true CU23415B7 (es) 2009-09-08

Family

ID=29286106

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20040252A CU23415B7 (es) 2002-04-30 2004-11-01 Derivados de 2,6- quinolinilo y 2,6- naftilo, procesos para su preparación y sus usos

Country Status (24)

Country Link
US (2) US7638630B2 (es)
EP (2) EP1501801B1 (es)
JP (1) JP2005535583A (es)
KR (1) KR100841165B1 (es)
CN (2) CN1649842A (es)
AR (1) AR039341A1 (es)
AT (1) ATE384699T1 (es)
AU (1) AU2003232472B2 (es)
BR (1) BR0309719A (es)
CA (1) CA2484954C (es)
CO (1) CO5450243A1 (es)
CU (1) CU23415B7 (es)
DE (1) DE60318839T2 (es)
ES (1) ES2298543T3 (es)
IL (1) IL164516A0 (es)
MX (1) MXPA04010673A (es)
MY (1) MY135218A (es)
NO (1) NO20045234L (es)
NZ (1) NZ536180A (es)
PL (1) PL373763A1 (es)
RU (1) RU2315041C2 (es)
TW (2) TWI267508B (es)
WO (1) WO2003093237A1 (es)
ZA (1) ZA200408447B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093237A1 (en) * 2002-04-30 2003-11-13 Ucb, S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
US7153889B2 (en) 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
EP1595870B1 (en) * 2003-02-20 2015-09-23 Ajinomoto Co., Inc. Process for producing phenylalanine derivative having quinazolinedione skeleton and intermediate for the same
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7145005B2 (en) 2004-05-12 2006-12-05 Abbott Laboratories 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
CA2610800A1 (en) 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
KR20090086539A (ko) 2006-11-14 2009-08-13 산텐 세이야꾸 가부시키가이샤 (치환 페닐 또는 치환 복소환) 카르보닐옥시 저급 알킬기와 에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2-디히드로퀴놀린 유도체
WO2008125215A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008125210A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases
WO2008138592A1 (en) * 2007-05-14 2008-11-20 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008138615A1 (en) * 2007-05-16 2008-11-20 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
EP2085407A1 (en) 2008-02-04 2009-08-05 Sahltech I Göteborg AB Treatment of idiopathic thrombocytopenic purpura
TWI510240B (zh) * 2008-05-12 2015-12-01 由具有取代氧基之２，２，４－三甲基－６－苯基－１，２－二氫喹啉衍生物組成之糖皮質激素受體激動劑
EP2467159A1 (en) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
US20150368213A1 (en) * 2014-06-20 2015-12-24 The University of Montana, Missoula, MT Novel Inhibitors of System Xc-
MX385777B (es) * 2014-12-24 2025-03-04 Lg Chemical Ltd Derivado de biarilo como agonista de gpr120.
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
JP7635962B2 (ja) * 2021-01-12 2025-02-26 国立大学法人山口大学 フルオロアルキル置換ビニルフルオロアルカンスルホニルアミドの製造方法
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
CN116410136B (zh) * 2023-03-03 2025-07-11 五邑大学 一种喹啉衍生物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2909214B2 (ja) * 1992-08-19 1999-06-23 フアイザー・インコーポレイテツド 置換ベンジルアミノ窒素含有非芳香族複素環化合物
US5550139A (en) * 1994-01-03 1996-08-27 The Wichita State University Serine protease inhibitors
JP2920741B2 (ja) * 1994-12-14 1999-07-19 参天製薬株式会社 新規１，３−ジアルキルウレア誘導体
WO1996018606A1 (en) * 1994-12-14 1996-06-20 Santen Pharmaceutical Co., Ltd. Novel 1,3-dialkylurea derivatives
JPH0987291A (ja) * 1995-09-26 1997-03-31 Wakamoto Pharmaceut Co Ltd 新規なアラニン誘導体
AU8191998A (en) 1997-02-04 1998-08-25 Trega Biosciences, Inc. 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
KR100554815B1 (ko) * 1997-08-22 2006-02-22 에프. 호프만-라 로슈 아게 엔-아로일페닐알라닌 유도체
PT1114028E (pt) * 1998-08-26 2007-02-28 Aventis Pharma Ltd Aza-biciclos moduladores da inibição da adesão celular
EP1175412A1 (en) * 1999-04-28 2002-01-30 Dr. Reddy's Research Foundation Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
US6280442B1 (en) * 1999-09-01 2001-08-28 Sdgi Holdings, Inc. Multi-axial bone screw assembly
US6399599B1 (en) * 1999-10-13 2002-06-04 Novartis Ag Substituted 2-oxo-1,4-diazacycloalkanes
WO2003093237A1 (en) * 2002-04-30 2003-11-13 Ucb, S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
CA2610800A1 (en) 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament

Also Published As

Publication number Publication date
EP1870402A1 (en) 2007-12-26
EP1501801B1 (en) 2008-01-23
TWI267508B (en) 2006-12-01
IL164516A0 (en) 2005-12-18
CO5450243A1 (es) 2004-10-29
CA2484954C (en) 2010-02-09
US20080064720A1 (en) 2008-03-13
EP1501801A1 (en) 2005-02-02
PL373763A1 (en) 2005-09-19
DE60318839T2 (de) 2009-01-22
MY135218A (en) 2008-02-29
NO20045234L (no) 2005-01-18
TW200616960A (en) 2006-06-01
AR039341A1 (es) 2005-02-16
NZ536180A (en) 2005-04-29
CA2484954A1 (en) 2003-11-13
KR100841165B1 (ko) 2008-06-24
DE60318839D1 (de) 2008-03-13
TWI268278B (en) 2006-12-11
RU2004135304A (ru) 2005-07-10
AU2003232472A1 (en) 2003-11-17
TW200404061A (en) 2004-03-16
CN1649842A (zh) 2005-08-03
ZA200408447B (en) 2006-07-26
JP2005535583A (ja) 2005-11-24
KR20040106425A (ko) 2004-12-17
ES2298543T3 (es) 2008-05-16
ATE384699T1 (de) 2008-02-15
BR0309719A (pt) 2005-02-09
WO2003093237A1 (en) 2003-11-13
RU2315041C2 (ru) 2008-01-20
MXPA04010673A (es) 2005-09-30
CN101200450A (zh) 2008-06-18
US7638630B2 (en) 2009-12-29
US20100105681A1 (en) 2010-04-29
AU2003232472B2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
ECSP077271A (es) Derivados de pirimidina
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
ECSP099327A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
ECSP066667A (es) Derivados de ciclohexano espirociclicos
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
AR057325A1 (es) Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
PA8570901A1 (es) Derivados de acil-4-carboxifenilurea, procedimientos para su preparacion y su uso
PA8592301A1 (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
UY29004A1 (es) Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
UY28482A1 (es) Nuevos compuestos
PA8582801A1 (es) Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa
GT200600258A (es) Derivados de n-(piridin-2-il)-sulfonamida
HN1999000106A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
HN2002000300A (es) Nuevos derivados de piperazina
HN2008000088A (es) Heterociclicos de 1,4-dihidropiridina- fusionada, procesos para preparar los mismos, su uso y las composiciones que los contienen.
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
DOP2006000243A (es) Derivados de pirazina
GT200600144A (es) 1h-quinazolin-2,4-dionas
HN2001000235A (es) Derivados puentes de piperazina
UY30865A1 (es) Nuevos analogos de piridina x 161
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
SV2007002315A (es) Derivados de octahidropirrolo[3,4-c]pirrol ref. pc32623a
ECSP045271A (es) Derivados de quinolina

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)